反应详情

The title compound was prepared using the same procedure as 3-Oxo-3,4-dihydro-2H benzo[1,4]thiazine-6-sulfonic acid {(R)-2-hydroxy-3-[(R)-5-(6-methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide (GSK-203344A) except substituting C-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-methylamine for C-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-methylamine. 1H NMR (400 MHz, CDCl3): δ8.72 (d, J=4.5 Hz, 1H); 8.19 (d, J=9.1 Hz, 1H); 7.59 (d, J=4.6 Hz, 1H); 7.35-7.42 (overlapping signals (3H); 7.11 (d, J=9.1 Hz, 1H); 6.30 (m, 1H); 4.54 (t, J=9.4 Hz, 1H); 4.01-4.08 (m, 1H); 3.99 (s, 3H); 3.58 (dd, J=8.8, 7.5 Hz, 1H); 3.49 (dd, J=14.6, 7.0 Hz, 1H); 3.44 (s, 2H); 3.27 (dd, J=14.7, 3:6 Hz, 1H); 3.08 (dd, J=13.4, 3.8 Hz, 1H); 2.99 (dd, J=13.1, 6.3 Hz, 1H); 2.62 (m, 1H). MS (ES) m/e 546 (M+H)+.